Ticker LaunchUplisting · BGLC
BioNexus Gene Lab Corp
Formerly BioNexus Gene Lab Coporation
BioNexus Gene Lab Corp (BGLC), already reporting to the SEC, moved up to Nasdaq Capital Market on Jul 21, 2023 with an offering at $4.00 per share. Network 1 was lead-left underwriter. Ortoli Rosenstadt advised the company and VCL Law advised the underwriters.
BioNexus Gene Lab Corp operates through subsidiaries in Malaysia that provide non-invasive liquid biopsy blood tests analyzing RNA changes to detect risk of 11 diseases, and that sell chemical raw materials to industrial, medical, automotive and electronics manufacturers in Southeast Asia.
- Status
- Uplisting
- Ticker
- BGLC
- Exchange
- Nasdaq Capital Market
- Listed
- Jul 21, 2023
- Price
- $4.00
- Market cap at IPO price
- $62.9M
- First filed
- Jan 29, 2019
- Underwriters
- Network 1
- Company counsel
- Ortoli Rosenstadt
- Underwriters' counsel
- VCL Law
- Sector
- Healthcare
More on this listing for subscribers
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 29, 2019
- Latest amendment Jul 17, 2023
- Final prospectus (424B4) Jul 21, 2023
- All filings on EDGAR CIK 1737523
Other Healthcare uplistings in 2023
- Agape ATP CorpATPC · Oct 12, 2023 · $7.6M